MARKET

DFFN

DFFN

Diffusion Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.4301
+0.0201
+4.90%
After Hours: 0.4240 -0.0061 -1.42% 19:59 04/03 EDT
OPEN
0.3791
PREV CLOSE
0.4100
HIGH
0.4500
LOW
0.3511
VOLUME
7.90M
TURNOVER
--
52 WEEK HIGH
6.49
52 WEEK LOW
0.2110
MARKET CAP
14.88M
P/E (TTM)
-0.1872
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average DFFN stock price target is 2.750 with a high estimate of 3.500 and a low estimate of 2.000.

EPS

DFFN News

More
  • DFFN: Evaluating TSC as Potential Treatment for ARDS
  • Zacks Small Cap Research · 1d ago
  • Diffusion Pharma To Evaluate Drug In COVID-19-Related Respiratory Distress, Sending Stock Higher
  • Benzinga · 3d ago
  • COVID-19-related actions - Healthcare
  • seekingalpha · 3d ago
  • Diffusion Pharmaceuticals Evaluating TSC Against Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients
  • GlobeNewswire · 3d ago

Industry

Biotechnology & Medical Research
-0.50%
Pharmaceuticals & Medical Research
-0.22%

Hot Stocks

Symbol
Price
%Change

About DFFN

Diffusion Pharmaceuticals Inc., formerly RestorGenex Corporation, is a clinical-stage biotechnology company. The Company is focused on developing standard-of-care treatments, including radiation therapy and chemotherapy. The Company's lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (TSC) is used in various cancer types, in which tumor oxygen deprivation (hypoxia) is known to diminish the effectiveness of treatments. The Company's Diffusion's technology is targeted at overcoming treatment-resistance in solid cancerous tumors by combining its lead product candidate, TSC, with standard-of-care radiation and chemotherapy regimens, thus effecting a better patient survival outcome without the addition of harmful side effects. Its clinical development plan targets TSC at the radiation and chemotherapy sensitization of hypoxic tumor types, with an initial focus on primary brain cancer (glioblastoma or GBM), pancreatic cancer, and brain metastases.
More

Webull offers kinds of Diffusion Pharmaceuticals Inc stock information, including NASDAQ:DFFN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DFFN stock news, and many more online research tools to help you make informed decisions.